-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cabozantinib S-malate in Relapsed Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cabozantinib S-malate in Relapsed Multiple Myeloma Drug Details: Cabozantinib s-malate (XL184, BMS907351, Cometriq) is a...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cabozantinib S-malate in Refractory Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cabozantinib S-malate in Refractory Multiple Myeloma Drug Details: Cabozantinib s-malate (XL184, BMS907351, Cometriq) is a...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Maplirpacept in Lymphoma Drug Details: Maplirpacept (TTI-622) is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Maplirpacept in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drug Details: Maplirpacept (TTI-622) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Maplirpacept in Diffuse Large B-Cell Lymphoma Drug Details: Maplirpacept (TTI-622) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Follicular Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Maplirpacept in Follicular LymphomaDrug Details:Maplirpacept (TTI-622) is under development for the treatment of relapsed and refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Fallopian Tube Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Maplirpacept in Fallopian Tube CancerDrug Details:Maplirpacept (TTI-622) is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Peritoneal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Maplirpacept in Peritoneal CancerDrug Details:Maplirpacept (TTI-622) is under development for the treatment of relapsed and refractory...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Cutaneous T-Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Maplirpacept in Cutaneous T-Cell LymphomaDrug Details:Maplirpacept (TTI-622) is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Epithelial Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Maplirpacept in Epithelial Ovarian CancerDrug Details:Maplirpacept (TTI-622) is under development for the treatment of relapsed and...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Relapsed Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Maplirpacept in Relapsed Multiple MyelomaDrug Details:Maplirpacept (TTI-622) is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Maplirpacept in Refractory Multiple MyelomaDrug Details:Maplirpacept (TTI-622) is under development for the treatment of relapsed and...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Peripheral T-Cell Lymphomas (PTCL)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Maplirpacept in Peripheral T-Cell Lymphomas (PTCL)Drug Details:Maplirpacept (TTI-622) is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PF-07901801 in Fallopian Tube Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Maplirpacept in Fallopian Tube Cancer Drug Details: Maplirpacept (TTI-622) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Cutaneous T-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Maplirpacept in Cutaneous T-Cell Lymphoma Drug Details: Maplirpacept (TTI-622) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Relapsed Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Maplirpacept in Relapsed Multiple Myeloma Drug Details: Maplirpacept (TTI-622) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PF-07901801 in Refractory Multiple Myeloma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Maplirpacept in Refractory Multiple Myeloma Drug Details: Maplirpacept (TTI-622) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Peripheral T-Cell Lymphomas (PTCL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Maplirpacept in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Maplirpacept (TTI-622) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PF-07901801 in Epithelial Ovarian Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Maplirpacept in Epithelial Ovarian Cancer Drug Details: Maplirpacept (TTI-622) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PF-07901801 in Peritoneal Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Maplirpacept in Peritoneal Cancer Drug Details: Maplirpacept (TTI-622) is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.